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As part of our commitment to fostering student 
interest in research, the William Beaumont 
Medical Research Honors Society at GW’s School 
of Medicine and Health Sciences (SMHS) is proud 
to introduce the 2012 edition of Fusion — a 
student-run research journal that serves as a forum 
for students to share their research experiences with 
the GW medical community. 
This year’s edition focuses on the theme of 
putting basic science research into clinical practice. 
Medicine is an incredibly dynamic and rapidly 
evolving field. At the same time, basic science is 
identifying new molecular pathways, genetic poly-
morphisms in disease, and targeted pharmaceutical 
therapies at an impressive rate. While these devel-
opments are aimed at advancing the medical field, 
the integration of these innovations into clinical 
practice also poses a unique challenge for today’s 
health care professionals.
Never before has the collaboration and coordi-
nation of researchers and health care practitioners 
been more important. As future medical profes-
sionals it is imperative that we seek to continue 
to integrate these dynamic aspects into our own 
Welcome to Fusion
Dear GW Community and Fellow Research Enthusiasts,
practice. However, learning these skills most often 
requires us to immerse ourselves in enriching 
experiences outside the classroom, and it is these 
endeavors that Fusion highlights. This publication 
features a “fusion” of clinical, basic science, and 
public health research, reflecting the experiences of 
a number of enthusiastic and dedicated members of 
the SMHS student body. We hope that as you enjoy 
reading the following articles you are inspired to 
seek out opportunities that will help strengthen 
your own skills as future health care professionals.
Lastly, we would like to thank all of our authors 
and artists who help to make Fusion a great success 
each year. We also extend our many thanks to our 
faculty advisor, Vincent A. Chiappinelli, Ph.D., 
interim associate vice president for Health Affairs 
and associate dean of SMHS, and the Office of the 
Dean for their generous support, and to SMHS 
Office of Communications and Thomas Kohout 
and Michael Leong for making Fusion a reality. 
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is  a  publication of the 
George Washington Univer-
sity School of Medicine and 
Health Sciences William H. 
Beaumont Medical Research 
Honor Society. 
This research journal is pub-
lished by students in col-
laboration with the Office of 
the Dean and the School of 
Medicine and Health Sciences 
Office of Communications 
and Marketing.
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the years to come. 
GW’s Beaumont Society 
was established at the School 
of Medicine in 1935 to 
encourage student research. 
The Society promotes the 
development of research 
knowledge, skills, and experi-
ences while gaining an appre-
ciation of the inf luence of 
research on the current and 
future practice of medicine. 
Once again, congratula-
tions to the Beaumont Society 
and its faculty advisors on 
a fantastic publication and 
I wish you the best in your 
future scientific endeavors.















interests that set them apart 
as individuals. It is critical 
that as students progress 
through medical school and 
post-graduate training there 
be opportunities to preserve 
and foster the development of 
these and additional interests. 
One way this is done is by 
encouraging the pursuit of 
individual research experi-
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c at ion to 
research 
and their willingness to take 
on the challenge of producing 
the sixth edition of their 
Letters
Jeffrey S. Akman, 
M.D. ’81, GME ’85 
I n t e r i m  V i c e 
President for Health 
Affairs, Dean, School 
of Medic ine and 
Health Sciences
Following the Route to Discovery
scientific journal, Fusion. This 
publication is an example of 
how our students frequently 
go beyond their didactic and 
clinical requirements to delve 
into finding the root causes 
of disease and discovering 
new therapies. The research 
published on these pages is a 
culmination of a wide-range 
of research interests, a lot of 
hard work, and desire to push 
the needle forward to ensure 
that health professionals have 
the information they need to 
make informed decisions. 
As an institution, GW is 
committed to research and 
the School of Medicine and 
Health Sciences is a leader in 
those efforts. I am extremely 
proud of our faculty for fos-
tering our student’s desire to 
learn, as well as for identifying 
opportunities for continued 
research in an environment 
where it is not always easy 
to attain financial support. 
As our health care system 
evolves to meet the needs of 
the future, research and dis-
covery will continue to grow 
in importance. The lessons 
medical students learn today 
will lay the foundation for 
successful medical careers in 
There are many ways to 
achieve a meaningful research 
experience, from a two-month 
summer experience to a 
decade of Ph.D. and post-doc-
toral training. In reflecting 
on my own career path as an 
M.D.-Ph.D. student, it is clear 
that the most important fea-
ture was not to be the student 
who got the highest test scores 
(that was never true), but to 
simply have the endurance 
and enthusiasm to persevere 
through an extended period 
of training, and to tolerate the 
inevitable failures and critical 
reviews inherent in research.
My primary motivation 
was not dependent upon 
whether a given project was 
clinically relevant. The poten-
tial clinical impact of basic 
science research, as well as 
clinical research, is diff i-
cult if not impossible to pre-
dict. I believe that the most 
important motivation for 
those pursuing research is an 
inherent curiosity and enthu-
siasm for learning how things 
work or determining how to 
make things work better. 
Students come to medical 
school with that curiosity and 
enthusiasm to learn about 
how the complexities of bio-
logical systems are related to 
clinical care. Unfortunately, 
it’s often lost, partly because 
of the way we teach in the 
pre-clinical years and also 
because as students become 
more exposed to clinical 
decision making it becomes 
self-evident that a lot of the 
biomedical science knowl-
edge that they committed to 
memory has relatively little 
relevance to patient care. 
Because of this disconnect, 
one may justifiably ask why 
there is such an emphasis 
on basic biology in medical 
school. I think the answer 
partly lies in the ability of 
scientific teaching to foster 
critical thinking and intel-
lectual curiosity. As students 
go on in clinical practice, 
whether this is combined with 
a research interest or not, it is 
important that they are intel-
lectually equipped to manage 
the more atypical patient 
presentations and critically 
challenge standard ways of 
treating patients.
It is here that those stu-
dents involved in research 
and who have contributed to 
Fusion have a special role. You 
can serve as role models for 
your peers by demonstrating 
a commitment to intellectual 
curiosity. And perhaps, with 
enthusiasm and perseverance, 
you will develop the skills 
and opportunity to devise 
new approaches to clinical 
care and challenge some of 
the more counter-productive 





[aja’waska] is a 
hallucinogenic 
be ve r a ge  t ha t 
i s  made  f rom 
two indigenous 
p l a n t s  f r o m 
the Northwest 
Amazon region, 
especially by the Kichwa tribe of Ecuador. 
Shamans in these regions have used the 
elixir for centuries, claiming it has 
diagnostic and curing effects, in addi-
tion to its psychedelics effects believed 
to serve as a route to the supernatural 
realm. Shamans of the community are 
very knowledgeable in its usage, as well 
as other Amazonian medicinal plants; 
however, until recently, Western medi-
cine was not readily available. With the 
recent construction of a road connecting 
the community to other small commu-
nities and the river launch point to the 
city, there are concerns of the potential 
blending of modern pharmacotherapy 
with traditional medicinal plants such 
as Ayahuasca.2
Studies of this brew have isolated 
its active substances and derivates, two 
of which are N,N-dimethyltryptamine 
(DMT) and a plant alkaloid from the 
β-carbolines. DMT is a natural psycho-
active indolealkylamine, a non-selective 
serotonin 5HT agonist. It has a high 
affinity for serotonin 5HT1A receptors, 
while the active metabolite bufotenine 
has higher affinity for 5HT2A. The 
active metabolite occurs as a result of 
metabolism by the cytochrome P450 
system CYP2D6. DMT is mainly inacti-
vated through the deamination pathway 
mediated by monoamine oxidase-A 
(MAO-A). β-carboline alkaloid is a well-
known potent MAO-A inhibitor. Thus, 
when dually ingested in the Ayahuasca 
drink, a β-carboline such 
as harmaline inhibits the 
breakdown of DMT and 
increases the synaptic levels 
of the active metabolite, 
bufotenine.3
After spending several 
days with the very small 
and isolated Kichwa com-
munity in the Napo region 
of Ecuador, I realize how 
mixing traditional sha-
manistic medicine and 
western pharmacotherapy 
could lead to potentially 
fatal consequences. The 
improved access to Western medical care 
for the Kichwa people and the influx of 
Western tourists, students, and volun-
teers, poses a great risk of mixing the use 
of Ayahuasca with their current pharma-
cotherapy. Common drug interactions 
of concern are selective serotonin reup-
take inhibitors (SSRIs) among others. 
This class of drugs is commonly pre-
scribed in the western world and when 
taken with Ayahuasca can cause a toxic 
increase in serotonin causing serotonin 
syndrome.3 This adverse drug reaction 
can have mild to life threatening symp-
toms caused by increased serotonergic 
activity. The classic clinical description 
includes changes in mental status, auto-
nomic hyperactivity, and neuromuscular 
abnormalities. However, symptoms can 
range from diarrhea, tremor, myoc-
lonus, dilated pupils, hyperthermia, and 
increased blood pressure and heart rate 
that may eventually lead to metabolic 
acidosis and shock. It is often difficult to 
diagnose because of the range of severity 
of the symptoms.1
After speaking with a Kichwa 
shaman, it was very clear that he 
was unaware of any interactions or 
adverse reactions that could occur with 
Ayahuasca or any other medicinal plant 
therapy because he was never exposed to 
such Western pharmacotherapy before. 
Therefore, it is in my opinion that sha-
mans of the indigenous communities in 
the Napo region of the Amazon receive 
some education about pharmacotherapy 
of the modern world and about fusing 
the indigenous shamanistic medicine 
with modern western medicine. It is also 
important that travelers and physicians 
treating those who may be traveling 
to indigenous communities be made 
aware of the potential risks including 
drug-drug interactions before taking 
Ayahuasca or other medicinal plants. 
REFERENCES:
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Perspectives 
The Use of Ayahuasca Among the Kichwa of Ecuador: The Potential Dangers  
of Mixing Western Pharmacotherapy and Traditional Shamanistic Medicine
Members of the Kichwa community of Rio Blanco in a traditional 
performance.
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During the 2010 
Ear thquake in 
Haiti, children 
under the age of 
12 accounted for 
65.9 percent of all 
deaths; they were 
eleven times as 
likely to die due 
to sustained inju-
ries, and twice as likely to die due to 
illness compared to adults.1 There is a 
disparity in options for treating children 
that becomes clearer in disasters that 
largely affect the pediatric population, 
necessitating a re-evaluation and restruc-
turing of current strategies in pediatric 
emergency management.
Emergency management is the dis-
cipline of preparing for and avoiding 
risks that have large catastrophic conse-
quences. It involves a coordinated effort 
from multiple professional fields with 
the main goal of public safety followed 
by the protection of resources and prop-
erty. There are four phases that work in 
sequence to reach this goal: mitigation, 
preparedness, response and recovery. 
Many resources are available that outline 
health care planning and mitigation in 
response to a disaster event. However, 
the majority of these plans focus on care 
for adults and wrongly assume that the 
same strategies will work for children. 
In a study of pediatric surgeons, 77 per-
cent felt, “definitely responsible” to help 
during a disaster, yet only 24 percent 
reported feeling “definitely prepared.”2 
Many emergency physicians have also 
felt less prepared and more uncomfort-
able with pediatric emergencies versus 
emergencies in adults.
Children are more vulnerable during 
disasters because they have impor-
tant biological differences that make 
them more susceptible to insults like 
disease, physical injury, and dehydra-
tion.3 Children also present special 
challenges during disasters, such as 
separation from caregivers and inability 
to relay important medical information. 
Reunification may be more difficult to 
achieve for younger children since many 
are unable to identify themselves, their 
parents or their caregivers. Additionally, 
many hospitals are not 
adequately equipped to 
handle the large varia-
tions in sizes that chil-
dren go through as they 
develop. This equates to 
sub-standard quality of 
treatment, especially for 
smaller children, since 
they are the least compatible with readily 
available adult-sized equipment.
There are some things that can be 
done to help address these problems. In 
preparation for a disaster, health care 
professionals should discuss emergency 
plans with patients and their families 
and suggest assembling a disaster tool 
kit.4 Health care professionals should be 
involved with organizations that perform 
drills in order to increase and test their 
disaster response ability. They should 
also try to advocate for pediatric-specific 
protocols in disaster planning. This will 
educate all types of health professionals 
on the basics of treating children and 
increase awareness on the differences 
between pediatric and adult medicine. 
Once a disaster involving children has 
occurred, health care professionals 
should determine and manage surge 
capacity by using an effective pediatric 
triage system. Determining the level 
of care each patient needs improves 
allocation of resources; with more 
attention and resources being spent on 
acutely injured and treatable victims.4 
Professionals should also understand 
the established communication system 
in order to increase the effectiveness of 
their efforts. Improved communication 
would also assist in reunification between 
separated children and families. Patients 
and their families should get adequate 
support on how to cope after a disaster. 
It is important for experienced profes-
sionals to work with children to guide 
and provide developmentally appropriate 
ways of dealing with their feelings.2
There is a widespread lack of con-
fidence and comfort in treating ill or 
injured children among health care 
professionals. It is important to address 
the discomfort and disparities in treating 
injured children as they make up a 
quarter of the U.S. population. Ideally, 
these suggestions will increase aware-
ness and improve pediatric disaster care. 
Future studies should determine the nec-
essary steps to implement pediatric spe-
cific procedures and policies in disaster 
preparedness and planning.
For more information about pediatric 
emergency management, visit www.
pedsem.com.
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Once a disaster involving children has 
occurred, health care professionals should 
determine and manage surge capacity by 
using an effective pediatric triage system.
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Melanoma is an 
aggressive form 
of cancer that 
has an increasing 
i n c i d e n c e  i n 





de ve lop  br a in 
metastases.2 An 
activating valine-
glutamate substitution at position 
600 of the B-RAF protein has been 
implicated in approximately 50 percent 
of melanoma cancers.3 The B-RAF 
protein is a serine/threonine protein 
kinase of the RAS-RAF-MEK-MAPK 
signaling pathway involved in growth 
and proliferation. GSK2118436 is a 
molecular inhibitor that selectively 
binds and blocks the activity of mutant 
B-RAF proteins. Early clinical trials 
show that GSK2118436 may control 
and reduce brain metastases from 
melanoma.4 Primary and secondary 
drug resistance has been observed in 
clinical trials of B-RAF drug inhibitors 
such as GSK2118436.5 The effects of 
combinatorial treatment of melanoma 
brain metastases with GSK2118436 and 
ionizing radiation therapy are currently 
unknown. The combined therapy could 
be toxic, neutral, additive or synergistic. 
By determining if GSK2118436 can 
increase the sensitivity of radiation 
resistant melanoma cells to ionizing 
radiation treatment, this study assesses 
the capability of GSK2118436 to 
synergistically kill or radiosensitize 
human BRAF mutant melanoma cell 
lines. 
Clonogenic survival assays were 
performed to assess in vitro cell survival 
following increasing doses of radiation 
(0–8 Gray or J/Kg). This assay establishes 
the relative sensitivity to radiation of 
the following BRAF mutant cell lines 
harvested from human melanoma 
tumors: A375, WM2664, WM35, and 
SKMEL5. Radiosensitization of cell 
lines was determined by comparison of 
survival with and without the B-RAF 
inhibitor, GSK2118436. Molecular 
inhibition of mutant B-R AF was 
confirmed by immunoblot analysis. 
BRAF mutant melanoma cell lines 
showed varying radiosensitivities to 
radiation treatment. Figure 1 shows the 
results of the radiation clonogenic assay 
establishing a radiosensitivity baseline. 
The radiosensitivity was determined 
with the cell lines listed in order of 
decreasing radiosensitivity: WM2664 > 
SKMEL5 > A375 > WM35. WM2664 
was the most sensitive to radiation 
with the highest survival fraction after 
2 Gray (SF2). WM35 was the most 
resistant to radiation with the lowest 
SF2 value. A375 and WM35 were 
selected as candidates for examining 
radiosensitivity effects of combinatorial 
GSK2118436 and radiation therapy. 
The results of this combinatorial therapy 
are shown in Figure 2. The survival 
fraction decreased significantly with low 
dose GSK2118436 combination in the 
radiation resistant cells (WM35). A375 
are semi-radiation sensitive cells and the 
response to B-RAF inhibitor was not as 
dramatic as seen in the radioresistant 
line WM35.
The B-RAF inhibitor GSK2118436 
increases radiation sensitivity in the 
radiation resistant, mutant BR AF 
melanoma cancer cell lines. Our results 
conf irm that melanoma cell lines 
demonstrate variable sensitivity to 
radiation therapy. Cell lines that were 
more radioresistant were more effectively 
radiosensitized by inhibition of mutant 
B-R AF by GSK2118436. Further 
Bradley T. Anderson, MSII 
Advisor: Erik P. Sulman, 
M . D . ,  P h . D . ,  T h e 
University of Texas MD 
Anderson Cancer Center
Radiosensitization of Melanoma Cell Lines  
Using Molecular Mutant B-Raf Drug Inhibitor GSK2118436 Treatment
 Continued on p. 6
Basic Science
FIGURE 1: Melanoma Cell Survival Curves. Survival curves for A375, WM35, WM2664, and SKMEL5 
performed at 0-8 Gy of ionizing radiation showing the relative radiosensitivity of human melanoma cancer cell lines. 


























































validation in vivo is ongoing. The data 
thus far suggest a role for the use of 
GSK2118436 in combined treatment 
with radiation for patients with B-RAF 
mutated melanoma brain metastases.
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Cold plasma treatment (CPT) can potentially 
be used in cancer therapy by generating reactive 
ion species that may induce tumor cell apoptosis.
 Continued from p. 5
FIGURE 2: Radiation Therapy Combined with GSK2118436. Survival curves at 0-4GY of ionizing 
radiation (IR) pretreated two hours before radiation with low (2.5nM) and high (7.5nM) doses of GSK2118436. 
Both survival curves show increased melanoma turmor cell death.
Plasma, the fourth 
state of matter, 
is composed of 
partially ionized 
gas conta ining 
electrons, excited 
molecules, free 
radicals and ions.1 
Historically, 
p l a s m a  c ou ld 
o n l y  b e 
produced at high 
temperatures or in vacuums, however, 
recent advances in plasma physics 
have led to the production of plasma 
at room temperature.2,3 Non-thermal 
atmospheric plasma, or “Cold Plasma” 
Cold Plasma Therapy as a Novel Chemotherapeutic Strategy
Jacob  K i r s c h ,  MS I I 
Advisor: Anthony Sandler, 
M.D. Children’s National 
Medical Center
is produced by applying a high voltage 
electric field to a plume of compressed 
gas. While theoretically any gas or 
m i x t u r e  o f 
g a s s e s  c a n 
be used, our 
g r o u p  u s e d 
helium due to 
the advantages 
o f  i t  b e i n g 
monatomic 
and chemically 
inert. Cold plasma treatment (CPT) can 
potentially be used in cancer therapy 
by generating reactive ion species that 
may induce tumor cell apoptosis. Our 
initial studies demonstrated efficacy in 
killing tumor cells in both in vitro and 
in vivo mouse models of neuroblastoma. 
We therefore sought to advance these 
findings by evaluating the effects of cold 
plasma in human neuroblastoma and 
normal fibroblast cell lines.


























































































































































































































































Radiation combined with GSK2118436
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FIGURE 1: Annexin and 7AAD staining in IMR-32 cells 48 hours after treatment with cold plasma for varying 
amounts of time. 
FIGURE 2: Annexin and 7AAD staining in Fibroblasts 48 hours after treatment with cold plasma for varying 
amounts of time
elucidate the chemotherapeutic effects 
of CPT by evaluating its effects on 
IMR-32 human neuroblastoma cells 
and human fibroblasts (ATCC 895.
sk). A constant dose of CPT was 
administered for 30, 60, and 120 
seconds, respectively. Cell apoptosis 
was analyzed by f low cytometry at 
four different time points following 
treatment with CPT: immediately, 24 
hours, 48 hours, and one week. Normal 
human fibroblasts were chosen to serve 
as a negative control for comparison. 
Staining for apoptosis (annexin V-FITC) 
as well as cell death (7-AAD) allowed 
us to differentiate between necrotic 
cells, which died through mechanisms 
unrelated to CPT, and cells that were 
induced to undergo apoptosis as a direct 
result of CPT. The potential utility of 
CPT as a chemotherapeutic agent is 
dependent on its ability to produce the 
latter.
Our study showed that CPT of 
neuroblastoma cells induced a three to 
six-fold increase in apoptosis compared 
to controls. CPT induced a dose-
response effect in the tumor cells, 
decreasing cell viability by up to 89 
percent 24 hours after treatment (data 
not shown) and 98 percent 48 hours after 
treatment (Figure 1). Conversely, CPT 
was largely ineffective in eliciting an 
effect on human fibroblasts; these cells 
maintained their viability compared 
to untreated controls both 24 hours 
and 48 hours post-treatment (Figure 
2). This effectively demonstrated that 
CPT can induce apoptosis of human 
neuroblastoma cells, without affecting 
normal human f ibroblasts. Cold 
plasma therefore represents a potential 
emerging adjunct in cancer therapy, 
as demonstrated by its selective and 
effective in vitro targeting of human 
neuroblastoma. The mechanism of this 
tumor selectivity is currently still under 
investigation, however it is believed to be 
mediated by the generation of reactive 
oxygen species.
Treatment Duration (seconds)
Annexin and 7AAD Staining in Fibroblasta Exposed to Cold Plasma
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The process of 
vision begins at 
the photorecep-
tors in the retina, 
which prov ide 
nearly 30 percent 
of the sensor y 
input to the brain. 
Neurodegenera- 
tive blinding dis-
eases are due to 
genetic defects 
t h a t  c a u s e 
abnorma l  d i f-
ferent iat ion or 
homeostat is of 
retinal photore-
ceptors, and such defects are the primary 
cause of visual impairment in diseases 
of the retina. The neural retina leucine 
zipper (NRL) transcription factor is 
a key regulator of rod photoreceptor 
differentiation and homeostasis. NRL 
functions as a molecular switch to 
produce rod photoreceptors from post-
mitotic retinal precursor cells.1 Lman1 
encodes ERGIC-53, a protein medi-
ating the transfer of a subpopulation of 
glycoproteins from the ER to the Golgi 
complex.2 ERGIC-53 has a secondary 
function in glycoprotein quality control 
and it is ubiquitously expressed.3 We 
identified the Lman1 gene as a direct 
transcriptional target of NRL. To iden-
tify the potential role of Lman1 in retinal 
degeneration, we investigated its regula-
tion and function in rod photoreceptors 
using Lman1 knockout mice. 
Chromatin immunoprecipitation 
followed by real-time quantitative 
polymerase chain reaction (ChIP-
qPCR) and enhancer analysis of the 
Lman1 enhancer element were used to 
validate the interaction between NRL 
and Lman1 promotor sequences. ChIP-
qPCR and enhancer analysis detected 
the Lman1 promotor as a direct target 
of NRL. 
Physiologic relevance of Lman1 
in  the  re t ina  wa s  te s ted u s ing 
Characterization of the Role of Lman1 in Retinal Degeneration
FIGURE 1:   Comparison of NRL antibody ChIP DNA to IgG control ChIP DNA showed a 15-fold difference  













































immunohistochemistry (IHC) in Lman1 
knockout mice. Retinas were collected 
from Lman1 -/- mice at 2 months and 
6 months of age. The retinas were 
sectioned, and IHC was performed 
against the Golgi markers GM130 
and Grasp65, glial marker GFAP, and 
the rod photoreceptor visual pigment 
rhodopsin. 
IHC showed reduction in Grasp65 
and rhodopsin in 2 month and 6 month 
old Lman1 -/- mice compared to WT, 
whereas no siginificant difference in 
GFAP was observed. IHC against 
GM130 a lso showed signi f icant 
reduction in 2 month old Lman1 mice 
compared to WT.
 Our results suggest that Lman1 has 
an important role in rod photoreceptor 
development and homeostasis. Function 
tests will be conducted to evaluate the 
retina of Lman1 -/- mice through light 
damage studies and electroretinography 
analyses. 
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FIGURE1: Brightfield pictures of HNE cells on D18. (A) HNE cells cultured on growth-factor reduced Matrigel 
proliferate into glandular-like acini. (B) HNE cells form tubule structures in collagen I matrix.
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FIGURE 3:  There was a significant difference in the normalized luciferase activity in HEK293T cells cotransfected 
with a Lman1 enhancer construct and mouse NRL (mNRL) compared to cells cotransfected with a control vector and 
































Constructs Cotransfected with mNRL
Submucosal 
glands — invagi-




ways  — a re  a 
major source of 
mucus produc-




hyperplasia is a primary histopatho-
logic feature in obstructive respiratory 
pathologies — such as cystic fibrosis 
and chronic rhinosinusitis — associated 
with mucus hypersecretion and obstruc-
tion of the sinonasal tract.1,2 While 
the morphogenesis of SMGs during 
fetal development is well described,3 
the underlying mechanisms that lead 
to invagination of the epithelium and 
differentiation of epithelial cells to glan-
dular cells with ductal tubules and acini 
are unknown. Glandular hyperplasia 
in respiratory tract mucosa is markedly 
understudied, reflecting the lack of an in 
Maureen Banigan, MSII 
Advisor: Xiaofang Wu, 
M.D., Children’s National 
Medical Center
Developing a 3D Glandular In Vitro Model from Human Airway Epithelial Basal Cells
vitro cell model system whereby respira-
tory tract epithelial cells differentiate 
into glandular cells.
The current paradigm in lung 
biology is that there are progenitor cells 
in respiratory tract epithelium poised to 
facilitate epithelial repair and remod-
eling. These cells are capable of under-
going epithelial invagination into the 
underlying basement matrix that results 
in the formation of SMG with ductal 
tubules and acini. The SMG progenitor 
cells in both mice and humans have been 
identified as basal cells (BCs) within the 
surface airway epithelium of the lower 
respiratory tract.4,5 Predictably, the 
progenitor cells in nasal and sinus epi-
thelium are also basal cells, but limited 
studies exist on BCs isolated from the 
upper respiratory tract. We hypothesize 
that BCs differentiate to form glands in 
a three-dimensional extracellular matrix 
A B
 Continued on p. 10
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FIGURE: (A) Growth kinetics of HNE cells with and without exposure to 100-ng/mL FGF9. The results represent the mean values from three different experiments. (B) Ten 
brightfield images of HNE acini were taken every five days until day 20. Acinar areas were measured in 25 individual acini by Image J (NIH). Fold changes of HNE acinar average 






















































and are triggered by inf lammatory/
immune response mediators and growth 
factors to produce glandular hyperplasia 
in disease states. To test this hypothesis, 
we developed an in vitro 3D system 
wherein BCs from primary epithelial 
cells differentiate into glandular struc-
tures when grown on different basement 
membrane matrices. 
Fluorescent activated Cell Sorting 
(FACS) analysis of purified human nasal 
epithelial (HNE) cells and human bron-
chial epithelial (HBE) cells derived from 
human airway epithelium indicated 
that 98 percent of cells were basal cells 
and immunofluorescence (IF) staining 
for basal cell markers supported this 
finding. We found that the morpho-
logical differentiation of BCs in in vitro 
culture is dependent upon extracellular 
matrix conditions. While HSE BCs 
differentiate into glandular acini when 
overlaid on Matrigel®, they differentiate 
into glandular tubules when embedded 
in collagen (Figure 1). Both glandular 
acini and glandular tubules formed by 
HNE cells in vitro expressed in vivo 
markers of mucous and serous glandular 
cells. Exposure of HNE basal cells to 
EGF, FGF7, and FGF9 significantly 
enhanced their proliferation rate, sug-
gesting that growth factors may play an 
important role as positive regulators of 
the morphogenesis and differentiation 
of submucosal glands in respiratory tract 
mucosa (Figure 2). Although statistically 
significant, the increased HNE acinar 
size seen after exposure to inflamma-
tory mediators (CXCL5, CXCL13, and 
GM-CSF) was small. 
Our developed in vitro glandular 
acinar model is a useful model for 
studying the effects of growth fac-
tors and other mediators on HSE and 
HNE glandular proliferation and 
differentiation. The use of basal cells, 
which can be cultured in a chemically 
defined medium, permits analysis in a 
controlled model system of the activity 
of growth factors and inf lammatory 
mediators added to the culture. Further 
investigation into the role of immune/
inflammatory response mediators and 
growth factors in de novo gland devel-
opment will allow identification and 
eventual circumvention of the mecha-
nisms that lead to SMG hyperplasia 
with subsequent mucus hypersecretion.
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Cardiovascular 
d i s e a se  i s  t he 
l e ad i ng  c au s e 
of death in the 
United States.1 
Coronary artery 
disease (CAD), in 
which atheroscle-
rotic plaque builds 
up and obstructs 
the arteries sup-
plying the heart, 
affects over 16.5 
million people in 
the United States.2 Nearly 500,000 
people in the U.S. are newly diagnosed 
with CAD each year.2
The current gold standard for 
diagnosing CAD is coronary angiography 
using coronary artery catheterization. 
However, only 60 percent of patients 
undergoing d iagnost ic coronary 
catheterization have obstructive CAD 
(≥50 percent stenosis of left main 
coronary artery or ≥70 percent stenosis 
of major epicardial vessel), while 39 
percent of patients undergoing elective 
coronary catheterization have no CAD 
(<20 percent stenosis in all vessels).3 
Given the risks associated with coronary 
catheterization and the expense of this 
procedure, it would be valuable to 
develop an alternative highly predictive 
test for CAD.3,4
There is evidence that specif ic 
changes in gene expression accompany 
CAD.2,5 Several studies have identified 
differentially expressed gene transcripts 
in blood samples associated with CAD, 
raising the possibility that detecting 
changes in transcript expression in 
patient blood samples may be a feasible 
means of predicting the presence of 
CAD.2,5 Therefore, transcript expression 
profiles of differentially expressed genes 
are the potential basis of a blood-based 
diagnostic test for CAD. 
To investigate the possibility of 
developing a test for CAD based on 
differential transcript expression, we 
used next-generation sequencing of 
blood sample RNA (RNA-seq) to 
identify Transcripts Associated with 
CAD (TRACs). While previous studies 
have used microarray-based methods 
to identify differential gene expression 
in CAD, we used RNA-seq because 
it provides the advantages of directly 
quantifying all known transcripts and 
allowing analysis of splicing and allele 
usage.5
Here, we show that RNA sequencing 
of blood samples identifies TRACs in 
our patient population. Blood samples 
were collected from patients without 
previously diagnosed CAD about 
to undergo non-emergency cardiac 
catheterization. As a midpoint analysis, 
from our coronary catheterization 
cohort we identified 10 patients with 
significant CAD (>20 percent stenosis 
of one or more arteries) and 10 patients 
without CAD (0 percent stenosis). 
These patients were matched for age 
and gender; no significant differences 
existed between groups for risk factors 
such as blood pressure, BMI, or diabetes. 
RNA was extracted from these blood 
samples and sequenced on the Helicos 
sequencing platform.
These preliminary RNA-seq digital 
gene expression data identif ied 151 
gene transcripts differentially expressed 
in patients with stenosis (> 1.5 fold 
change) passing a t-test corrected for 
FIGURE: FOLD ELEVATION OF SELECTED GENE TRANSCRIPTS IN CAD: 
Fold elevation of selected gene transcripts in patients with CAD (>20 percent stenosis) relative to the transcript 
expression level of the same gene in patients without CAD (0 percent stenosis). (p < 0.01)
PLD2: Phospholipase D2
ESR2: Estrogen Receptor ß
SHMT2: Serine Hydroxymethyltransferase 2 (a/b = splice isoforms)
SHMT2 (a)ESR2PLD2
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Diagnosis of Coronary Artery Disease by Deep Sequencing of Blood
Translational
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multiple testing (p < 0.01). These 151 
TRACs included 17 of 23 transcripts 
associated with CAD identified in a 
2008 microarray-based study.5 The 
in the SHMT2(b) isoform, illustrating 
the ability of this method to assess 
expression of splice variants.
These preliminary results demon-
strate identification of 151 gene tran-
scripts differentially expressed in patients 
with CAD using RNA sequencing. After 
analysis of all enrolled 
patients is complete, 
the next planned step 
in this ongoing study is 
to use these TRACs to 
train a Support Vector 
Machine classification 
algorithm to identify 
CAD in new patient 
samples. This expression profile algo-
rithm will be used to develop a blood-
based rapid PCR array or ELISA test 
to provide a rapid, minimally invasive 
CAD detection test. The possibility 
of preventing needless catheterizations 
with this blood test has the potential 
to improve patient outcomes while 
increasing time and cost efficiency of 
CAD diagnosis.
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fold elevation of Phospholipase D2, 
Estrogen Receptor ß, and Serine 
Hydrox ymethylt ransfera se  gene 
transcripts in CAD are highlighted 
in the Figure. Of particular interest 
is the greater than 4-fold increase in 
expression of the SHMT2(a) isoform, 
and the greater than 4-fold decrease 
[T]ranscript expression prof iles of 
differentially expressed genes are the 
potential basis of a blood-based diagnostic 
test for coronary artery disease. 
  CIS NIND OIND PPMS RRMS SPMS ALL
 Number (n) 10 38 20 38 74 12 192
 Female, n 6 30 8 19 42 6 111
 Median Age (years) 39.5 48 39 52 38.5 53 45.5 
  (20-57) (27-65) (40-62)  (20-67) (18-68) (32-67) (18-68)
TABLE: Demographics and clinical characteristics of patients and controls.
Multiple Sclerosis 
( M S )  i s  a n 
immune-medi-
a t e d  d i s o rde r 
of  the cent ra l 
nervous system 





t h e  c a u s e  o f 
M S  r e m a i n s 
unknown, it is 
believed that reactive oxygen species 
(ROS) released from macrophages and 
microglial cells in the CNS react with 
myelin to result in the pathology seen 
in MS. Specifically, ROS react with 
myelin fatty acid side chains resulting 
in cell damage and a breakdown in 
Blood Brain Barrier (BBB) integrity.1 
Two end-products generated from 
the lipid peroxidation of myelin are 
4-Hydroxynonenal (4-HNE) and 
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8-Isoprostane (8-IsoP), and are therefore 
expected to be increased in the CNS of 
MS patients.2 Uric acid is an antioxidant 
that would be expected to increase in the 
serum of MS patients as a host defense 
mechanism against oxidative stress. 
The goal of this study was to 
identify biomarkers of oxidative stress 
in the cerebrospinal f luid (CSF) of 
MS patients. The discovery of a novel 
biomarker whose levels correlate with 
the amount of oxidative damage in the 
CSF would offer a quantifiable entity 
that could be used as a diagnostic tool 
and as a measure of disease progression. 
This study investigates 4-HNE and 
8-IsoP as potential CSF markers.
Enzyme-linked Immunosorbent 
Assays (ELISA) were optimized to 
quantify the concentrations of 4-HNE 
histidine adducts and free 8-IsoP in 
the CSF of a blinded cohort of sub-
jects. Serum uric acid levels were also 
obtained as a measure of antioxidant 
activity. A total of 124 patients with MS, 
10 patients with a Clinically Isolated 
Syndrome (CIS) not yet classified as 
MS, 38 patients with Noninflammatory 
Neurologic Diseases (NIND), and 
20 patients with Other Inflammatory 
Neurologic Diseases (OIND) were 
included. Patients were classified as 
Identifying CSF Biomarkers of Oxidative Stress in Patients with Multiple Sclerosis
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FIGURE 1: Serum levels of uric acid were obtained and compared with CSF levels of 8-IsoP and 4-HNE. Uric acid showed a significant 











































having Primary Progressive MS (PP-
MS) (n=38), Relapsing Remitting 
MS (RR-MS) (n=74), or Secondary 
Progressive MS (SP-MS) (n=12).
4-HNE was found to be significantly 
elevated in the CSF of MS patients 
compared to controls (p<0.05), while 
8-IsoP showed only a modest elevation. 
The increase in both species supports 
the proposed role of oxidative stress in 
the pathogenesis of MS. In addition, 
serum levels of uric acid correlated 
with CSF levels of 4-HNE but not 
with 8-IsoP (Figure 1). The correlation 
between 4-HNE and uric acid suggests 
that the two may be associated with 
MS pathology; specifically, oxidative 
stress causes an increase in uric acid 
concentration as an antioxidant defense 
mechanism.
Among MS subtypes, only PP-MS 
and RR-MS showed a signif icant 
increase in CSF levels of 4-HNE com-
pared to controls, the former being 
most statistically significant (Figure 2). 
PP-MS is characterized by a gradual 
decline in disability with no distinct 
periods of remission, while RR-MS 
shows periods of partial remission.3 
Hence, 4-HNE levels should indeed 
be highest in these patient groups 
FIGURE 2: The absorbance of each patient sample was measured and analyzed using standard curves to determine 4-HNE and 8-IsoP concentrations. Among MS subtypes, 
PP-MS and RR-MS patients had significantly higher CSF levels of 4-HNE compared to NIND controls (p<0.05; a), whereas SP-MS did not reach statistical significance. PP-MS 
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Supervillin is a 
205-kD F-actin 
binding protein 
encoded by the 
SVIL gene that 




s k e l e t o n  a n d 
p l a sm a  me m-
brane.1 The pro-
t e i n  lo c a l i z e s 
within lipid-raft 
domains of the plasma membrane, and 
potentially functions in cellular adhesion 
and motility. While SVIL is expressed in 
numerous tissues, expression is highest in 
striated, cardiac, and smooth muscle.2
Archivillin is a 297-kD, alternatively 
spliced isoform of SVIL that is specific 
to skeletal muscle tissue and myogenic 
cell lines. Archivillin also binds directly 
to F-actin and is associated with the 
cytoskeletal protein, dystrophin, as well 
as the adhesion proteins, caveolin-3, 
and vinculin. It has been proposed that 
archvillin may play a role in early myo-
genesis and muscle cell differentiation. 
Additionally, it may contribute to the 
integrity of the myotendinous junction, 
which serves to distribute longitu-
dinal forces developed during muscle 
contraction.3
The role of the SVIL gene in skeletal 
A Variant in the Supervillin Gene is Associated  
with Lean Muscle and Adiposity Phenotypes
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muscle has been further explored through 
its relationship to the androgen receptor 
(AR). AR activation and its association 
with increased muscle mass has been 
previously elucidated. The SVIL gene 
has been found to act as a co-regulator 
of the AR in skeletal muscle, increasing 
transactivation. This result indicates 
that SVIL may play an important role 
in muscle development and repair. 
Additionally, previous studies have 
suggested the potential for cross-talk 
between the AR and vitamin D receptor 
(VDR) mediated by co-regulators of the 
AR as a mechanism for increasing VDR 
transactivation. Consequently, the SVIL 
gene may play a role in VDR functioning 
and associated bone health.4,5
Our study sought to further describe 
the relationship between the SVIL 
gene and phenotypes associated with 
lean muscle, bone, and adipose tissue 
by examining single nucleotide poly-
morphisms (SNPs) that may have a 
functional relationship to the SVIL gene.
We studied 155 ethnically diverse, 
healthy volunteers (average age 22.05± 
4.6 yrs females and 23.31 ± 5.61 yrs 
males) recruited from the Bone and 
Muscle Study performed at the University 
of Massachusetts. We genotyped two 
SNPs found in SVIL (rs36027845 and 
rs10437410), and examined associations 
between these SNPs and measures of 
lean muscle tissue, bone mineral density, 
and adiposity. Mean quantitative muscle, 
compared to SP-MS patients who are 
in a state of chronic remission. 
CSF levels of 4-HNE were indepen-
dent of both patient age and gender, 
while 8-IsoP levels were independent 
of gender but increased with age. This 
implicates 4-HNE, but not 8-IsoP, as a 
marker for patients of all demographics. 
A future study already in progress 
involves the development of ELISA 
assays to measure additional products 
of oxidative stress. CSF levels of these 
products will be analyzed and compared 
to the levels of 4-HNE, 8-IsoP, and 
uric acid.
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TABLE 1: In males, a single copy of the G allele for a SNP located near the SVIL gene (rs36027845) was associated 
with decreased total lean muscle and total arm lean muscle mass, as well as increased total percent tissue fat and 
total fat. No significant results were observed in females.
Significant Results
 SNP Phenotype (units) Sex P-value N: adjusted mean +
 SVIL rs36027845 % Tissue fat M 0.0190 AA (N=31; 20.2 ± 1.1) 
     AG/GG (N=35; 23.9 ± 1.1)
  Total fat (g) M 0.0175 AA (N=31; 16455 ± 846) 
     AG/GG (N=35; 19358 ± 794)
  Total lean (g) M 0.0157 AA (N=31; 59894 ± 819) 
     AG/GG (N=35; 57034 ± 769)
  Arms lean (g) M 0.0216 AA (N=31; 7193 ± 140) 
     AG/GG (N=35; 6755 ± 131)
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bone, and adipose measurements were 
compared in relation to SNP genotypes 
using analysis of covariance (ANCOVA) 
methods.
The SVIL gene and associated 
supervillin protein play a functional 
role in maintaining the integrity of 
the cytoskeleton of the cell. Previous 
studies have also implicated the SVIL 
gene as an important co-regulator of the 
androgen receptor in skeletal muscle, 
and it has been suggested that SVIL may 
increase transactivation of the vitamin 
D receptor.4,5 Associations between the 
SVIL gene and phenotypic variations in 
muscle, bone, and adipose tissue have 
not been previously studied.
The present study reports significant 
associations between a variant in the 
SVIL gene (rs36027845) and decreased 
total lean muscle mass and arm lean 
muscle mass, as well as increased percent 
tissue fat and total body fat in males. 
Pupasuite 3.1, a web-based SNP analysis 
tool that is used to identify potential 
functional properties of a variant, sug-
gests this SNP affects transcription factor 
binding. Our findings were sexually 
dimorphic as no significant findings were 
established in females. There were no 
significant findings between the genetic 
variants in the SVIL gene of interest and 
phenotypes associated with bone.
These results are consistent with pre-
vious studies that have investigated the 
role of the SVIL gene and the associated 
supervillin protein in muscle develop-
ment, and provide further evidence that 
the SVIL gene may play an important 
role in early myogenesis and regulation 
of skeletal muscle development via co-
regulation of the androgen receptor. An 
inverse relationship between skeletal 
muscle and adipose tissue was observed 
in males with the genetic variant, indi-
cating that the polymorphism may also 
be associated with an increased risk for 
adiposity. Additional study is needed 
to further elucidate the function of the 
SVIL gene in skeletal muscle growth 
and development as well as identify 
implications in disease processes of the 
musculoskeletal system.
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Osteoporotic 
fractures cause 
injuries that result 
i n  s i gn i f ic a nt 
morbidity 
and morta l it y. 
Substantial 
effort has been 
made to identify 
persons at risk 
for osteoporotic 
fracture so that 
preventative 
me a s u r e s  c a n 
be initiated in a 
timely fashion. To date, one of the 
best predictors of fracture is bone 
mineral density (BMD).1 If it were 
possible to identify persons at high 
genetic risk for developing low bone 
density, preventative strategies might be 
employed as early as childhood. 
Rivadeneira et al recently performed 
a meta-analysis of five genome-wide 
association studies of femoral neck and 
lumbar spine BMD in 19,195 subjects 
of Northern European descent. They 
identified 20 single nucleotide poly-
morphisms (SNPs) reaching genome-
wide significance that mapped to genes 
related to bone metabolism in signaling 
pathways.2 However, bone structure is 
not determined by signaling pathways 
alone. Past studies indicate that bone 
and muscle are interconnected tissues 
and that the mechanical forces of 
muscles play a major role in determining 
bone quality.3,4
We sought to determine whether 
the SNPs identified by Rivadeneira et al 
found to be associated with higher bone 
density (an element of bone quality) 
would be predictive of additional mea-
sures of musculoskeletal health such as 
skeletal muscle and bone volume in a 
population of young, healthy adults. 
The study population included 753 
college-age subjects (449 female; 304 
male; average age 24 yrs) recruited to 
undergo a 12-week strength-training 
program. Measurements of upper arm 
muscle volume, strength, and cortical 
bone volume were collected prior to 
and following resistance training. The 
cohort was genotyped for three SNPs 
(rs1366594, rs2941740, rs87938) dem-
onstrated to be associated with fracture 
risk in genome-wide association studies. 
Hardy-Weinberg equilibrium was tested 
in each SNP using a chi-square test. 
Associations between mean phenotypes 
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and genotypes were tested using an 
ANCOVA with age and baseline weight 
as covariates (cortical bone adjusted for 
age only). For those associations showing 
a signif icant F-test, pair-wise post 
hoc comparisons were performed and 
resulting p-values adjusted for multiple 
comparisons using the Sidak method.
Our results demonstrated that 
females that were homozygous for the 
recessive allele (n=46) for the rs2941740 
SNP demonstrated significantly larger 
pre-exercise upper-arm skeletal muscle 
volume compared to females hetero-
zygous for that SNP (p=0.026). Males 
with two copies of the dominant A allele 
for rs87938 demonstrated significantly 
larger pre-exercise upper-arm skeletal 
muscle volume compared to males with 
two copies of the rare G allele (p=0.008). 
No significant association was found for 
the rs1366594 SNP in males or females 
for the measured 
phenotypes. 
Our data sug-
gest that SNPs pre-
viously shown to 
be associated with 
BMD/fracture 
r isk (rs2941740 
and rs87938) are 
a l so  a s soc iated 
with upper arm 
muscle volume. 
These findings are 
consistent with 
the mechanostat 
hypothesis, which posits that there 
should be a close relationship between 
bone strength (or weakness) and muscle 
size/force. According to the mechanostat 
hypothesis, healthy bones dynamically 
adapt to skeletal loads, the majority 
of which come from muscular forces. 
Although moderate-to-vigorous physical 
activity has been reported to be associ-
ated with a hip fracture risk reduction 
of 45 percent in men and 38 percent 
in women, the exact contribution of 
physical activity and muscle strength on 
BMD and fracture risk remains poorly 
delineated.5 Further study of the inter-
play of genetic influences on bone and 
muscle health may lead to a more robust 
ability to predict fracture risk.
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Although moderate-to-vigorous physical 
activity has been reported to be associated with 
a hip fracture risk reduction of 45 percent 
in men and 38 percent in women, the exact 
contribution of physical activity and muscle 
strength on BMD and fracture risk remains 
poorly delineated.5 
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Adequate vitamin 
D  l e v e l s  a r e 
essential for bone 
health and muscle 




levels of vitamin 
D  h a v e  b e e n 
correlated with 
f r a c t u r e  r i s k 
a n d  f r a i l t y . 2 
Recent genome 
wide association 
studies (GWAS) have identified single 
nucleotide polymorphisms (SNPs) in the 
vitamin D binding protein that influence 
circulating levels of vitamin D and might 
be correlated with deficient states.3,4 
Identification of genetic variants that 
influence vitamin D homeostasis may 
lead to early identification of individuals 
at risk for vitamin D deficiency.
The goal of this study was to further 
delineate the influence of four loci [GC 
(rs2282679), CYP2R1 (rs2060793), and 
NADSYN1 (rs12785878, rs3829251)] 
that have been strongly associated with 
circulating vitamin D levels. We strove 
to explore whether these loci might 
influence changes in skeletal muscle as a 
result of resistance training. NADSYN1 
is a novel locus for association with 
vitamin D status. There is evidence that 
CYP2R1 is a key enzyme underlying 
25-hydroxylation of vitamin D in the 
liver, and so is a crucial first step in 
vitamin D metabolism. GC encodes 
vitamin D binding protein and is 
strongly associated with circulating 
concentrations, which affects the 
delivery of circulating vitamin D.3,4
The population used for this study 
was derived from a large multicenter 
study (FMS) designed to identify genetic 
variants that influence muscle size and 
strength and individual variability 
in response to resistance training. 
Our cohort included 753 college-aged 
subjects (449 female, 304 male) who 
underwent 12 weeks of supervised 
resistance training on 
the nondominant arm. 
At the beginning and 
upon complet ion of 
the exercise protocol, 
arm muscle volume was 
measured via MRI and 
strength measurements 
(one repet it ion max 
[1RM] and maximal 
voluntary contraction [MVC]) were 
taken. The study participants were 
genotyped for four genetic variants 
(rs2282679, rs2060793, rs12785878, 
and rs3829251) previously demonstrated 
to be associated with circulating levels of 
vitamin D in a cohort of 4501 persons of 
European ancestry.3,4 Mean phenotypes 
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FIGURE 1: Significant associations of the rs12785878 genotype and percent change in MVC strength in 
Caucasian males.
were compared among genotypes 
using ANCOVA with age and baseline 
weight as covariates (bone phenotype 
adjusted for age only). For co-dominant 
associations showing a signif icant 
F-test, pair-wise post-hoc comparisons 
were performed and resulting p-values 
adjusted for multiple comparisons using 
the Sidak method.
Our goal was to determine whether 
The identification of genetic variants that 
influence vitamin D homeostasis may lead 
to early detection of individuals at risk for 
vitamin D deficiency.
 Continued on p. 18
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FIGURE 2: Significant associations of the rs12785878 genotype and difference in whole muscle volume in 
Caucasian males.
SNPs that have exhibited an association 
with circulating vitamin D levels are 
also associated with skeletal muscle 
size and strength, and their response 
to resistance training. We found that 
males with two copies of the common 
allele for rs12785878 demonstrated a 
significantly larger increase in skeletal 
muscle volume (p=0.035) with resistance 
training and a greater percent change 
in MVC (p=0.026). No associations 
with any of our measured phenotypes 
were demonstrated with the other three 
SNPs. 
Our results demonstrate that certain 
SNPs that are associated with higher 
levels of circulating vitamin D are also 
associated with changes in skeletal 
muscle size and strength in males. We 
found that males in the FMS cohort 
with the common allele of rs12785878 
demonstrated a significantly greater 
increase in skeletal muscle strength 
following resistance training. This 
SNP is located in the promoter of 
the DHCR7 gene that encodes the 
enzyme 7-dehydrocholesterol (7-DHC) 
reductase. This enzyme converts 7-DHC 
to cholesterol, thereby removing the 
substrate from the synthetic pathway 
of  v it a min D3,  a  precur sor  of 
25-hydroxyvitamin D3.4 The effect of 
this enzyme on vitamin D status requires 
further investigation. Our results suggest 
novel roles for this gene and potential 
directions for future research. The 
identification of genetic variants that 
influence vitamin D homeostasis may 
lead to early detection of individuals at 
risk for vitamin D deficiency. This may 
lead to early screening and subsequent 
prevention of various bone diseases such 
as osteoporosis and fractures in males.
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FIGURE: Comparison of Pre-Operative and One-Year Post-Operative Radiographs
Proteus syndrome 
(PS) is a rare dis-
order involving a 
hamartomatous 
overgrowth with 
le s s  t ha n 10 0 
confirmed cases.1 
Bone and con-
nective tissue are 
the most common 
tissue types that 
undergo over-
growth in Proteus 
syndrome with local gigantism, hemi-
hypertrophy, exostoses, macrodac-
tyly, skull anomalies, limb-length 
discrepancy, kyphosis, and scoliosis 
constituting common manifestations, 
orthopaedic management is crucial.1,2 
There are only six reports in the ortho-
pedic literature that deal directly with 
treatment of scoliosis or kyphosis in PS. 
This limited literature has demonstrated 
difficulty in attaining lasting curve sta-
bilization, unpredictable tissue reactions 
to surgery, and complicating blood loss 
and thromboses.2–5 
Here, we present a case of severe 
kyphoscoliosis associated with PS in 
order to address the safety and efficacy of 
surgically correcting a spinal deformity 
in PS. A male patient was followed 
from the age of eleven to the age of 
fifteen and received surgical treatment 
for progression of severe kyphoscoliosis 
associated with PS with posterior spinal 
instrumentation and fusion, a process 
in which the joints of the spine are 
removed, rods are fixed to the spine, 
bone graft is placed, and the spine heals 
as one solid fusion mass so that curved 
growth is arrested. 
Our patient was satisfactorily cor-
rected from scoliotic curves of 65o to 
17oat C6-T5, 88o to 39o at T5-T10, 41oto 
20o at T10-L4, and from a kyphotic 
curve of 92o to 65o at T3-T10 with 
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no complications and his correction 
remains stable one-year post-operatively 
(Figure). 
To our knowledge, this is the first 
reported case of current deformity 
correction strategies employing spinal 
osteotomies, thoracic pedicle screws, and 
vertebral de-rotation for the correction 
of the kyphoscol iosis a ssociated 
with PS. This strategy is contrasted 
with the unsuccessful correction in 
previously reported cases, which may 
be attributable to their employment 
of second generation instrumentation 
using hooks, wires, or limited screw 
fixation. Conflicting recommendations 
have been given as to when surgical 
stabilization of spinal deformity in PS is 
warranted, but since the intelligence and 
life span of PS patients are normal, since 
spinal deformity may cause secondary 
restrictive pulmonary disease, and 
since severe kyphoscoliosis can cause 
neurological compromise, early surgical 
correction of kyphoscoliosis may be 
indicated. 
Fusion ✦ 201220
This case report is, by no means, 
a definitive statement on the safety 
or eff icacy of surgically correcting 
kyphoscoliosis in PS. However, the fact 
that our patient’s spinal deformity was 
effectively corrected without thrombotic 
complicat ion and without curve 
recurrence one year post-operatively 
shows that safe and effective correction 
is possible. Future studies could aim to 
more thoroughly examine the outcome 
of current orthopaedic strategies in 
correction of spinal deformity in PS 
patients. 
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Adenotonsil-
lectomy, the sur-
gical removal of 
a patient’s tonsils 
and adenoids, is 
one of the most 
commonly per-
formed proce-
dures in children 
in the  United 
States. There are 
no current guide-
lines to determine 
whether a patient should be admitted for 
inpatient observation after undergoing 
adenotonsillectomy, leaving much room 
for physician and hospital variation. 
Concern for postoperative complica-
tions may be an impetus for the decision 
to admit a patient after adenotonsil-
lectomy. It is well known that children 
with obstructive sleep apnea (OSA) are 
at greater risk of postoperative airway 
collapse, respiratory depression, and 
hypoxemia than patients without the 
diagnosis.1, 2, 3 This tendency can be 
exacerbated by the use of opioids for 
peri- and post-operative pain, particu-
larly in the minority of children who 
metabolize codeine via an alternate 
pathway and may accumulate excess 
active metabolite in the bloodstream.1, 4 
The objectives of this retrospec-
tive analysis were to 1) determine the 
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average percent of adenotonsillectomy 
patients admitted based on their age 
and presence of OSA or other “flagged” 
comorbidities (complex chronic condi-
tions such as cystic fibrosis, congenital 
abnormalities, etc). across 24 pediatric 
hospitals in the country, and 2) to 
identify practice variations if they exist 
amongst these group, using data from 
the Pediatric Health Information System 
(PHIS) collected over a one-year period.
Analysis of children undergoing 
adenotonsillectomy in twenty-four 
pediatric hospitals from July 2009 to 
June 2010 was conducted using PHIS. 
Patient characteristics were compared 
with hospital length of stay. Patients that 
were admitted overnight (defined as a 
length of stay > 1 day) were classified as 
inpatient cases. Children were divided 
into four groups based on age (0-2 
years, 2–3 years, 3-5 years, and greater 
than 5 years) and presence/absence of 
comorbidities (+/- OSA, +/- “flags”) and 
inpatient admission rates were compared 
and contrasted. (Table) 
Across all hospitals, younger patients 
(0-2 years of age) are more regularly 
admitted as inpatient (86.7 percent 
inpatient admission rate) than all other 
age groups. In addition, patients with 
OSA are more likely to be admitted 
than their age-equivalent counterparts 
without obstructive sleep apnea, as are 
patients who are flagged with a clinical 
diagnosis of a complex chronic condi-
tion. Across all age groups, 46.9 percent 
of patients with OSA were admitted, 
while 21.6 percent of patients without 
OSA were admitted. Similarly, 68.7 
percent of patients with PHIS “flags” 
were admitted, while only 28.8 percent 
of patients without these “flags” were 
admitted. (Table) 
As the burden of health care costs 
rises, physicians must consider how they 
allocate hospital resources. It is unwar-
ranted to admit every patient under-
going adenotonsillectomy, but it is cru-
cial to avoid postoperative complications 
in high-risk patients. This data clearly 
shows that physicians are aware of the 
increased risk in certain patient popula-
tion groups, reflected by their increased 
inpatient admission rates. These high 
risk groups include: age under two 
years, diagnosis of OSA, and diagnosis 
of a “flagged” comorbidity. However, 
although this data demonstrates clear 
trends for increased admission rates 
in certain groups, there is substantial 
practice variation. In patients that are 
not at high risk for surgery, such as a five-
year-old patient without any comorbid 
diagnosis, the practice variation is even 
more significant.
It is our hope that this study, along 
with future ones, will help to establish 
 Continued from p. 19
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  All age groups 0–2 Years 2–3 Years 3–5 Years Older than 5 Yrs 
  (n=29918) (n=895) (n=3277 (n=8370) (n=17376)
ALL PATIENTS 31.1 86.7 69.3 33.7 19.9 
  (n=29918) (n=895)  (n=3277) (n=8370) (n=17376)
 – OSA  21.6  85.7 68.6 29.0 15.5 
  (n=22665))  (n=539)  (n=2273)  (n=6155)  (n=13698)
  + OSA 46.9 88.2 70.9 46.7 36.5 
  (n=7253) (n=356)  (n=1004)  (n=2215)  (n=3678)
  - Flags 28.8 84.9 67.9  31.5 18.0 
  (n=28143) (n=717)  (n=3019) (n=7875) (n=16532)
+ Flags 68.7 93.8 85.7 69.3 57.8 
  (n=1775)  (n=178) (n=258)  (n=495) (n=844)
  - OSA/ - Flags 37.6  84.2 67.2 27.5  14.2 
  (n=5282)  (n=378) (n=1428)  (n=1607)  (n=1869)
 - OSA/ + Flags 64.7 93.3 87.9 58.0 48.0  
  (n=649) (n=84)  (n=131)  (n=181)  (n=253)
 + OSA/ - Flags 53.0  86.2 69.5 42.9 33.0 
  (n=2834)  (n=231)  (n=622)  (n=872)  (n=1109)
 + OSA/ + Flags 82.5  94.3 82.6  88.5 74.1 
  (n=570)  (n=83)  (n=90)  (n=162) (n=235)
 OSA = Obstructive Sleep Apnea, Flags = presence of at least one comorbidity flag
TABLE: Percentage of children in selected age and clinical groups admitted after adenotonsillectomy
concrete guidelines for inpatient admis-
sion of pediatric adenotonsillectomy, 
for patients with and without comorbid 
conditions. 
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Prospective Blinded Laboratory Assessment of Prophylactic  
Antibiotic Compliance in a Pediatric Outpatient Setting 








(VUR) be placed 
on cont inuous 
antibiotic 
prophylaxis 
(C A P)  i n  a n 
attempt to prevent 
ascending urinary tract infections 
(UTI) that can lead to renal scarring.1 
While CAP is commonly prescribed in 
ambulatory care settings to impede the 
development of UTIs, it is important 
to note that patient compliance to 
recommended regimens remains to be 
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a perpetual issue. Compliance rates 
for patients diagnosed with VUR and 
prescribed prophylaxis were shown 
to be as low as 40 percent.2 Although 
compliance has been well studied in 
pediatric patients, prior studies for 
UTI prophylaxis have focused on 
using indirect methods such parental 
questionnaires and pharmacy claims 
data. The establishment of compliance 
by methods such as urine test analysis 
can allow for a more concrete perception 
of true compliance as subjective 
measurements tend to be inflated.3
To our knowledge we conducted the 
first prospective, single blinded study 
that objectively assessed compliance 
by measuring urine antibiotic levels in 
children being prophylactically treated 
for VUR. Children aged 0-18 years 
taking trimethoprim prophylaxis were 
recruited to take part in the study. 
The subjects were previously unaware 
of the study and approached to be 
enrolled during follow-up appointments. 
Urine samples were collected and sent 
to a commercial lab (NMS Labs) to 
determine the antibiotic levels. Of 
those approached, 97 percent consented 
to participate (n=54). Recruitment of 
eligible patients was prematurely ended 
because preliminary analysis of the 
data revealed very high compliance. 
The adherence rate was found to 
be 91 percent. Age, sex, self-report 
of compliance, duration of time on 
antibiotics, insurance status, history of 
breakthrough infection, surgery, history 
of pyelonephritis and hospitalization 
were not associated with compliance.
 Continued on p. 22
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Our compliance rate of 91 percent 
contradicts much of the reported values 
for the treatment of UTIs in the pediatric 
population and prophylaxis compliance, 
which is generally notoriously poor.4,5 
The referral of patients with VUR by 
a primary care provider to a pediatric 
urologist might facilitate compliance 
because the seriousness of the condi-
tion becomes more apparent, especially 
as it made clear that poor compliance 
will likely result in the need of surgery. 
Furthermore, a specialist can focus on a 
single issue for the duration of the entire 
visit to ensure that better parental clarity 
and understanding is achieved as com-
pared to a primary care setting where 
multiple issues demand attention. Future 
studies should measure compliance in 
both other sub-specialty and general 
pediatric clinics. If proper compliance for 
prophylactic treatment is not established, 
perhaps pediatric urologist should be 
more involved with the care regardless 
of the future likelihood of surgery.
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 Antibiotic Cases susceptible (%) Cases resistant (%)
 Cefazolin 0 (0%) 41 (100%)
 Clindamycin 38 (92.7%) 3 (7.3%)
 Vancomycin 41 (100%) 0 (0%)
 Tetracycline 35 (85.4%) 6 (14.6%)
 Oxacillin 0 (0%) 41 (100%)
 Gentamycin 41 (100%) 0 (0%)
 Rifampin 41 (100%) 0 (0%)
TABLE: Antibiotic Resistance and Susceptibility to MRSA.
The prevalence 




i n f e c t i o n  i s 
i n c r e a s i n g  i n 
the hospital set-
ting.1 The rise of 
antibiotic resis-
tant pathogens 
continues in the 
modern American 
hospital despite 
evolving hygienic practices. As a major 
concern to all surgeons, proper prophy-
lactic treatments can help reduce the 
rate of new MRSA infections and mor-
tality. The National Surgical Infection 
Prevention Project (NSIPP) uses guide-
lines published in 1993, which state that 
cefazolin or cefuroxime are sufficient 
for surgery prophylaxis. The same 
report also indicates that vancomycin 
or clindamycin only be considered if 
the patient has a beta-lactam allergy. 
The NSIPP states that for best results, 
prophylaxis be started at least 60 min-
utes before operations and be continued 
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for only 24 hours after completion.2 
Although cefazolin continues to remain 
the mainstay for prevention of wound 
infection, our study indicates that it is 
ineffective against MRSA. This study 
aims to demonstrate that clindamycin 
or vancomycin should become the pre-
ferred treatment in the prevention of 
MRSA infections. 
We retrospectively evaluated 82 
patients who presented with hand 
infections to Washington Hospital 
Center from the years 2003–09; these 
patients were then operated upon. The 
specimens obtained during the initial 
evaluation and treatment were cultured 
and subjected to antibiotic susceptibility 
testing (Table). Only patients who 
had cultures positive for MRSA were 
selected for relevant data analysis. The 
following antibiotics were selected 
for testing susceptibility to MRSA: 
cefazolin, clindamycin, vancomycin, 
tetracycline, oxacillin, gentamycin, and 
rifampin. All information, including 
patient demographics, was obtained 
from patient charts. 
Forty one of 82 (50 percent) patients 
had cultures testing positive for MRSA. 
Cefazolin and oxacillin had no effect 
in preventing or treating MRSA as all 
positive cultures (n=4) showed bacterial 
Prevalence and Treatment of Methicillin-Resistant Staphylococcus Aureus (MRSA) 
in Hand Infections Presenting to an Urban Setting
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resistance. Vancomycin, gentamycin, 
and rifampin were effective in all cases 
(n=41). Clindamycin was not resistant in 
92.7 percent (n=38) of MRSA cultures. 
Tetracycline demonstrated efficacy in 
treating 85.4 percent (n=35) of MRSA 
cultures. 
The choice of empiric antibiotic is 
becoming increasingly difficult since 
cefazolin has long been favored despite 
its ineffectiveness in preventing MRSA.3 
The CDC has not yet published 
guidelines for MRSA prophylaxis during 
surgical procedures. Surgeons must 
rely on institutional guidelines or the 
National Surgical Infection Prevention 
Project’s (NSIPP) recommendation, 
which cites a paper published in 1993. 
Given that these guidelines were 
published almost two decades ago, 
newer and more effective antibiotics 
should be considered for surgical wound 
prophylaxis.
The rate of community acquired 
MRSA hand infections in an urban 
setting is higher than previously sus-
pected and the rate of MRSA positive 
cultures in our sample group is 50 
percent (n=82). Resistance to cefazolin 
and oxacillin was found in all cultures 
whereas vancomycin, gentamycin, and 
rifampin demonstrated no resistance. 
Clindamycin and tetracycline had sub-
stantially more efficacy than cefazolin or 
oxacillin with MRSA susceptibility rates 
at 92.7 percent and 85.4 percent respec-
tively. Although our patient sampling 
was relatively small, our subjects were 
good indicators of the general popula-
tion presenting to an urban hospital. 
This data should be taken into account 
when managing seemingly routine 
hand infections given that the treat-
ment options are different for MRSA 
infections. Specifically, based on our 
findings, cefazolin and oxacillin should 
be avoided as empiric antibiotics in favor 
of vancomycin, gentamycin, rifampin 
or clindamycin and tetracycline when 
preventing potential MRSA infections.
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Corpus Callosum DTI Measurements in Neurofibromatosis Type I and Normal Controls
Neurofibro- 
m a t o s i s  t y p e 
1  (NF-1)  i s  a 
common inher-
ited disorder with 
a prevalence of 
approximately 
1 in 2500-3000 
births. The dis-
ease affects the 
bra in in many 
ways, including 
structural abnormalities, such as macro-
cephaly and enlargement of the corpus 
callosum. The presence of cognitive 
deficits in NF-1 patients has lead to 
numerous investigations trying to find 
correlations between structural brain 
abnormalities and cognitive dysfunc-
tions. Several studies have linked cog-
nitive deficiencies in NF-1 patients to 
enlargement of the corpus callosum.1,2
The pathophysiological basis of 
corpus callosum enlargement (CCE) 
is not well understood. Four leading 
hypotheses to explain CCE have been 
A m i r  N o o r ,  M S I I 
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TABLE: Averaged data of several measurements used to compare NF-1 patients to matched control patients 
without NF-1.
proposed: 1) increased number of 
commissural fibers due to reduction 
in apoptosis; 2) excessive myelination 
resulting in larger axons; 3) increased 
extracellular fluid, and 4) myelinopathy 
associated with vacuolation, or a com-
bination of all four of these factors.3 
Imaging parameters, such as diffusion 
tensor imaging (DTI) have been used 
in adults to further evaluate structural 
features of CCE in adult NF-1 patients.3 
DTI measures, such as mean diffusivity 
(MD), fractional anisotropy (FA), axial 
and radial diffusivity, allow for indirect 
assumptions regarding brain structure. 
MD reflects the size of the interstitial 
space that allows for overall molecular 
diffusion. FA relates to the directionality 
of diffusion that is mainly affected by the 
architecture of the environment around 
the interstitial space. Axial diffusivity 
(AD) represents the dominant direction 
 Continued on p. 24
 Averaged Two Observers NF-1 Controls P-value
 Skull (mm^2) 15326 14344 0.0001
 CC-Skull Ratio 0.04900 0.03894 0.0001
 Radial Diffusivity 0.00040 0.00037 0.023
 Axial Diffusivity 0.00140 0.00148 0.0002
 Apparent Diffusion 0.00078 0.00098 0.067 
 Coefficient (ADC)
 Fractional Anisotropy 0.71711 0.74969 0.0012
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of diffusion along the long axis of fibers. 
Radial diffusivity (RD) ref lects the 
average diffusion of directions perpen-
dicular o long axis. The goal of our study 
was to investigate the pathophysiological 
basis of corpus callosum enlargement 
in NF-1 patients through these DTI 
measurements. 
Patients were consecutively selected 
from institutional data base with the 
inclusion criteria being: having an estab-
lished diagnosis of NF-1, brain imaging 
with DTI sequence, abnormally high 
corpus callosum to skull ratio. Patients 
with complications of NF-1 that could 
affect size of the corpus callosum were 
not included in this study. Subjects were 
age and gender matched with normal 
controls that were randomly selected 
from the radiology database. Manual 
regions of interest (ROI) were placed 
over the corpus callosum for DTI mea-
surements using DTI-Studio by two 
independent researchers, one blinded 
to diagnosis. Fifteen NF-1 patients 
and matched controls were analyzed. 
The corpus callosum to skull ratio 
was found to be significantly different 
between the experimental and control 
group (p=0.0001). For NF-1 patients 
we found: a trend to lower apparent 
diffusion coefficient (ADC, p=0.067), 
significantly higher radial diffusivity 
(p=0.023), signif icantly lower axial 
diffusivity (p=0.0002), 
and significantly lower 
fractional anisotropy (FA, 
p=0.0012).
The s igni f ic ant ly 
lower axial diffusivity 
in NF-1 patients can 
indicate that there are 
more crossing fibers in 
the corpus callosum of in 
these patients than in the normal con-
trols. Further studies using comparative 
DTI tractography may be helpful in fur-
ther investigating this stipulation. The 
significant increase in radial diffusivity 
can be explained by a variety of factors 
that can account for a larger interstitial 
space, including thinner myelin sheaths, 
increased interstitial fluid, smaller axons, 
or a combination thereof. The trend of 
lower ADC may indicate low axonal 
diameter, as ADC has been shown to 
more strongly correlate with axonal 
diameter without the myelin sheath. In 
Idiopathic Transverse Myelitis and Arteriovenous Malformations:  
A Chart Review of 94 Patients for More Efficient Diagnoses
Idiopathic trans-
ve r s e  mye l i t i s 
(ITM) is a clin-
ic a l  s yndrome 
caused by a focal 
inf lammation of 
the spinal cord 
causing demy-




tions (AVMs) are shunts fed by arteries 
normally supplying the neural tissue.2 
ITM and spinal cord AVMs present 
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similarly in a clinical setting. Sensory 
changes in legs and some form of bowel 
or bladder dysfunction are common 
clinical characterizations. The similarity 
in presentation of these conditions poses 
a problem for quick and effective treat-
ment due to their different etiologies. 
When an AVM is detected, treatment 
is aimed at halting the progression of 
the disease.2 Diagnosis usually rests on 
a positive CT angiography test in spinal 
cord AVMs. In addition, there is a slight 
variance in sensory level, defined as the 
most caudal level at which sensation 
is intact. For ITM the most common 
sensory level in adults is the midthoracic 
region.3 Most arteriovenous malforma-
tions result in a thoracolumbar sensory 
level.4 For AVMs, prognosis depends 
on the extent of ischemia and necro-
tizing myelopathy present at the time of 
diagnosis, indicating the importance of 
the timely recognition of disease.5 The 
delay in performing CT angiography to 
rule out AVMs and lack of knowledge 
of differentiating signs on presentation 
give cause for evaluation.
A retrospective review was performed 
of 94 cases of myelopathy referred for 
angiogram, comparing subjects whose 
future studies we will correlate abnormal 
corpus callosum DTI markers with cog-
nitive functions in NF-1 patients to see 
if relationships exist that can be used as 
predictors of cognitive deficits in young 
NF-1 patient.
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The trend of lower ADC may indicate low 
axonal diameter, as ADC has been shown 
to more strongly correlate with axonal 
diameter without the myelin sheath. 
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final diagnosis was ITM versus AVM. 
The aim was to assess any differences 
between ITM and AVM to provide 
more efficient diagnoses in the future. 
Gender demographics of the examined 
94 patients with ITM and AVMs were 
relatively equal, with 55 percent males 
and 45 percent females. Substantially 
more males (76 percent) were affected 
by AVMs in our patient population 
compared to females (24 percent).
In terms of clinical characterization 
based on physical examination, ITM 
and AVM patients were found to have 
slightly impaired functioning in lower 
extremities in strength tests, while their 
upper extremities appeared unaffected. 
80 percent of all patients were found 
to have sensory changes in their lower 
extremities, while just 7 percent were 
found to have sensory changes in their 
upper extremities. 75 percent of ITM 
and 59 percent of AVM patients expe-
rienced bladder or bowel dysfunction. 
As expected, the majority (60 percent) 
of ITM patients had an acute onset 
of disease, while 65 percent of AVM 
patients had a progressive onset. In 
terms of response to treatment, it was 
found that 55 percent of ITM patients 
showed improvement with steroids, 
while only 19 percent of AVM patients 
showed improvement. Also, 59 percent 
of AVM patients were found to have a 
vascular risk factor such as hypercho-
lesterolemia, hypertension, or diabetes 
mellitus, in comparison to 45 percent 
of ITM patients.
These data demonstrate that while 
characterizing the clinical differences 
between ITM and AVMs still remains 
somewhat clinically ambiguous, there 
are clinical markers that can lead to a 
more timely diagnosis. While a posi-
tive spinal angiogram still remains the 
most accurate way of distinguishing an 
AVM, a lack of response to steroids also 
likely indicates that vascular etiology in 
the spine may be involved. A thorough 
patient history including onset of the 
disease, acute versus progressive, may 
prove to be more indicative of a partic-
ular diagnosis. Additional evaluation of 
the importance that risk factors such as 
hypercholesterolemia, hypertension, and 
diabetes mellitus play in AVMs may also 
lead to a more efficient diagnosis and 
therefore better prognosis for patients.
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Panic d isorder 
i s  one  of  t he 
most  common 
anxiety disorders 
in Pa rk inson’s 
d i s e a s e  ( PD) 
with a prevalence 
of 10 percent-30 
p e r c e n t . 1  I n 
addition, there is 
a high prevalence 
of atypical ‘panic-
like’ anxiety disturbances correlated with 
motor and antiparkinsonian medication 
fluctuations in PD.2 One previous study 
reported distinct demographic and 
clinical features in individuals with PD 
and panic disorder as compared to PD 
subjects without anxiety, suggesting 
that panic disorder may be uniquely 
associated with PD and useful as a 
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Familial Aggregation of Panic Disturbances in Parkinson’s Disease
marker associated with disease etiology 
or prognosis.3 To investigate the validity 
and significance of panic disorder as a 
phenotypic subtype in PD, this family 
study investigated the heritability 
of panic disorder and ‘panic-like’ 
symptoms in PD.
Part icipants were adults with 
idiopathic PD and their first-degree 
relatives. They were recruited from 
movement disorder practices in the 
greater Baltimore area. Panic disorder 
status was determined by a psychiatrist 
as part of a comprehensive psychiatric 
evaluation. Case probands with PD 
and panic disorder (PD-PANIC, n=20) 
and a comparison group of non-anxious 
PD probands (PD-NA, n=17), defined 
as having no history of any anxiety 
disorder, no current mood disorder 
or major psychotic disorder, were 
identified. The sample included 222 
first-degree relatives (114 PD-PANIC 
relatives and 108 PD-NA relatives).
Evaluations to determine panic 
status in relatives were conducted by 
phone. When relatives were deceased, 
unreachable, or unwilling to participate; 
informant ‘proxy’ interviews were 
conducted by interviewing another 
family member or spouse. 
Demographic and clinical variables 
in PD-PANIC and PD-NA probands 
were compared using t-tests and the 
chi-square statistic. Significance was set 
a priori at p < 0.05. The odds of panic 
disorder and ‘panic-like’ phenomena 
in first-degree relatives were estimated 
using logistic regression by the method 
of generalized estimating equations, 
 Continued on p. 26
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 Characteristic PD-PANIC Probands PD-NA Probands P 
  (n=20) (n=17)
 Sex, No. (%)
  Male 11(55) 11(65) 0.55
  Female 9(45) 6(35)
 Current age, years 61.2(7.6) 70.8(8.4) 0.001
 Education, years 16 (3) 17(3) 0.32
 MMSE Total 28.7(1) 28.8(1.3) 0.76
 Age at PD Symptom Onset, years  49.1(9.3) 63.9(12.5) 0.0002
 Age at PD Diagnosis, years 50.6(9.4) 64.7(12.4) 0.001
 PD Symptom Duration, years 12.1(7.4) 6.9(6.9) 0.04
 Cumulative LDOPA Use, mg 815.1(587.7), n=18 442.4(205.1) 0.02
 Agonist Use, No. (%) 4(22), n=18 8(47) 0.12
 Hoehn & Yahr Stage Score 2.3(0.9) 2(0.9) 0.12
 Motor Fluctuations, No. (%) 11(73),n=15 3(18) 0.002
 UPDRS Sub-scores
  I (Mentation, Mood) 3.9 (3), n=18 1.1(1.1) 0.001
  II (ADL) Off 15.3(7.6), n=18 10.2(5.8) 0.03
  II (ADL) On 13.1(8), n=16 9.8(5) 0.15
  III (motor) 20.3(9.8), n=18 15.4(9.6) 0.16
  IV (Therapy complications) 5.3(3.3), n=18 2.2(3.8) 0.02
Mean (SD): UPDRS – Unified Parkinson’s Disease Scale; ADL – Activities of Daily Living
TABLE 1: Demographic and Clinical Features of PD-PANIC and PD-NA Probands
which accounts for within-family 
correlation among relatives.4 
Table 1 shows the demographic 
and clinical features of the PD-PANIC 
and PD-NA probands. As compared 
to the PD-NA probands, PD-PANIC 
probands were significantly younger 
(p=0.001), had a longer duration of PD 
(p=0.04), higher L-dopa doses (p=0.02), 
and greater ADL disability when in the 
‘off ’ state (p=0.03). However, they had 
comparable PD severity as measured 
by the Hoehn and Yahr stage and the 
UPDRS Motor sub-score. 
As shown in Table 2, the prevalence 
and odds of panic disorder and ‘panic-
like’ disorder is greater for relatives of 
PD-PANIC probands when compared 
to PD-NA probands [OR=16.13, 
p=0.01]. Regression analyses showed 
that the significant group differences 
in prevalence rate persisted after 
controlling for potentially confounding 
variables: younger age of PD-PANIC 
probands, presence of current depressive 
disorder in probands, higher prevalence 
of panic phenotype in female relatives, 
and higher prevalence of the panic 
phenotype in directly interviewed 
relatives. 
The finding that panic disorder and 
‘panic-like’ disturbances are familial in 
PD suggests that they may be genetically 
based and not simply accounted for 
by exposure to dopaminergic therapy 
or a reaction to motor impairment. 
The similarities between PD-PANIC 
probands and a previously described 
subgroup of ‘younger-onset’ PD patients 
suggests that panic-type anxiety may be 
an additional clinical marker for earlier 
onset PD and possibly an endophenotypic 
feature that co-segregates with relatives 
at increased risk for this PD variant.5 
Given the implications of these findings 
and the high prevalence of panic 
disorder in patients with PD, routine 
screening for panic phenomena in 
patients with PD should be considered.
 Characteristic of Relative Odds Ratio (95% CI) P
 Group
  Case 16.13 (1.82–142.7) 0.01
  Control 1.0 
 Sex
  Female 4.08 (1.25–13.3) 0.02
  Male 1.0 
 Type of Interview
  Direct 3.14 (0.96–10.3) 0.06
  Proxy 1.0 
 Characteristic of Proband Odds Ratio (95% CI) P
 Proband age
  PD-PANIC 0.984 (0.91–1.05) 0.55
  PD-NA1.0 
 Proband Depression Status
  Current Depression 1.08 (0..35–3..27) 0.90
  No Depression 1.0
TABLE 2: Adjusted Odds Ratios for Panic Disorder and “Panic-like” Disturbances
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tion services for 
a l l type 2 dia-
betes patients.1 
However, not all 
pat ients, espe-
cia l ly minority 
patients, receive 
t e s t ing  on  a n 
annual basis.2 Factors such as cost of 
service, time spent in the referral pro-
cess, misinformation about the disease 
process, young age, and poor glycemic 
control prevent patients from receiving 
eye care.3 Fundus photography has been 
proposed as a follow-up diagnostic tool 
to annual fundus examination, given 
their comparable eff icacy.4 Fundus 
photography was studied as opposed to 
dilated eye examination by a specialist, as 
the cost of service and referral wait-time 
is less of a burden for our underserved 
population. This study was designed to 
identify patient factors that contributed 
to a low rate of screening among our type 
2 diabetes patients. These factors could 
be used to flag patients deemed high risk 
of not receiving these services.
351 patients were selected randomly 
from our photography database. The 
patient population most frequently 
self-identified as Hispanic (n=265) and 
female (n=218). The average age of 
patients was 52 ±10 years. Race and sex 
Perceptions of Glycemic Control and Frequency of Type 2  
Diabetes Fundus Photography
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did not associate significantly with any 
variable. Patients in the study were asked 
to complete a bilingual questionnaire. 
Survey responses were grouped into 
four main categories for analysis: screen 
frequency, years with a diagnosis of type 
2 diabetes, retinopathy, and perception 
of glycemic control. If a patient selected 
a poor or fair response for their glycemic 
control, they were grouped into the lower 
than moderate group. If the patient 
selected a good or excellent response 
they were grouped into the better than 
moderate group. Electronic medical 
records were then used to associate 
most recent hemoglobin A1C (HbA1c) 
and retinopathy diagnosis at the time of 
photography, to the responses. 
These categories were then evalu-
ated: The HBA1C level was associated 
with the patient responses to provide 
an objective measurement of glycemic 
control in this population. The responses 
consisted of lower than moderate (LTM; 
Most Recent HbA1C= 8.7 ± 2.0 per-
cent); moderate responses (Most Recent 
HbA1c= 8.44 ± 1.9 percent); and better 
than moderate (BTM; Most Recent 
HbA1C=7.7 ± 1.9 percent). Data was 
analyzed using Fischer’s exact test.
The frequency of receiving fundus 
photography was not significantly asso-
ciated with the number of years diag-
nosed with type 2 diabetes, nor was it 
significantly associated with the patient’s 
subjective level of control. The patient’s 
perception of control was significantly 
associated with years diagnosed with 
type 2 diabetes — with patients who 
have had type 2 diabetes less than or 
equal to 10 years more likely to state 
BTM than LTM levels of control. Also, 
patient perception is not associated with 
a diagnosis of retinopathy. The presence 
of retinopathy is not associated with 
screen frequency, but is associated with 
years diagnosed with type 2 diabetes, as 
was expected.
Other studies have shown an associa-
tion between measured levels of glycemic 
control and screen frequency in an estab-
lished fundus photography program.5 
In this study, perception of glycemic 
control was not associated with rate of 
attendance. For example, those patients 
who state LTM levels of control were 
not less likely to attend eye screening 
services than a patient who states BTM 
levels of control. As a result, perceptions 
of glycemic control should not be used 
to classify patients as high risk of non-
attendance in patient populations with 
similar demographics. Further research 
is needed to determine if other patient 
or provider variables, such as underlying 
mental illnesses, economic issues, or 
provider biases, influence the frequency 
of obtaining fundus photography.
REFERENCES:
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FIGURE: Increments in PPV between the administrative databases and the clinical registries were greatest when 
a one day window in terms of procedural dates were included. Further increases resulted in minimal increases in PPV
 Associations Fisher Exact P Odds Ratio
 Screen Frequency  
  Years with T2DM 0.37 0.76
  Subjective Level of Control 0.44 0.75
 Subjective Level of Control  
  Years with T2DM 0.014* 0.41
  Retinopathy 0.15 1.62
 Retinopathy  
  Years with T2DM <0.000001† 6.72
  Screen Frequency 0.32 0.77
TABLE: Fisher’s exact test testing and odds ratio of responses tested at 95% Confidence. Values with a P<0.05 
are considered statistically significant.
Cardiovascu- 
lar diseases (CVD) 






In Canada, CVD 
h a s  r e d u c e d 
the average life 
expec tancy by 
2.8 years.1 While 
ca rd iac proce-
dures are an effective method routinely 
used to treat CVD, they are often 
costly and should be closely monitored. 
Administrative databases, initially 
developed for the purpose of tracking 
patient volume and hospital activities, 
are potentially powerful tools for cardiac 
procedure surveillance due to their rep-
resentativeness, availability, and capture 
of data over many years at relatively low 
cost.2 However, they must first be vali-
dated against clinical registries in order 
to ensure accuracy. 
The purpose of this study was to 
determine the validity of coding of 
Validation of Cardiac Procedure Codes in Canadian  
Hospital Administrative Databases
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cardiac procedures in the Canadian 
Institute for Health Information (CIHI) 
administrative databases, and compare 
them with the Cardiac Care Network 
(CCN) clinical registry of cardiac 
procedures. The CIHI cohort is a 
centralized population-based database 
that is collected by the hospital ’s 
administrative staff and contains only 
demographic information from all 
hospital discharges across Ontario. 
The CCN database is very cohort 
specific and is collected by trained nurse 
abstractors, including only patients 
who have undergone cardiac surgery. In 
addition to demographic information, 
and disease for racial and ethnic minority 
populations — a literature review. J Natl Med 
Assoc. 101:430–437
3. Hartnett, ME, Key IJ, Loyacano NM, Horswell 
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4. Taylor CR, Merin LM, Salunga AM, Hepworth 
JT, Crutcher TD, O’Day DM, Pilon B. (2007). 
Improving diabetic retinopathy screening 
ratios using telemedicine-based digital retinal 
imaging technology. Diabetes Care. 30:574–578
5. Leese GP, Boyle P, Feng Z, Emslie-Smith A, 
Ellis JD. (2008). Screening uptake in a well-
established diabetic retinopathy screening 







































 Continued from p. 27
CLINICAL 29
L A SE R i s  a n 
acronym for Light 
Amplification 
by St imu lated 
E m i s s i o n  o f 
Radiation. This 
stimulated emis-
s i o n  h a s  t h e 
potential to cause 
m a t e r i a l s  t o 
deform. Because 
the eye’s optical 
system is capable 
of focusing radia-
tion, it is particularly vulnerable.1 
Reports of aircrafts exposed to lasers are 
a growing concern due to the increasing 
availability and decreasing price of hand-
held lasers.2 In the first six months of 
2011, there were 671 cases reported to the 
Civil Aviation Authority (CAA) of the 
United Kingdom. Many countries have 
Stephanie Waggel, MSII 
Advisor: Ewan Hutchison, 
Head of Aeromedical 
Centre and Occupational 
Health, United Kingdom 
Civil Aviation Authority
criminalized directing lasers at aircrafts 
and operational procedures to deal with 
exposure have been established.3 While 
nearly all of the reported exposures 
have not been associated with long term 
physical damage, the increasing power 
of available lasers raises the possibility. 
There are currently no guidelines 
for a rapid self-assessment to assist in 
determining if professional treatment 
should be sought after eye illumination 
from a laser. Eye damage, particularly 
retinal damage, can be painless, and 
may result in a delay in medical care.3 
Uncertainty can also send individuals 
to see a physician unnecessarily. The 
Aviation Laser Exposure Self-Assessment 
(ALESA) was created as a convenient 
means to assist in self-evaluation after a 
laser beam incident. 
A review of laser incidents reported 
to the CAA was conducted. To center 
the ALESA on aspects of the incident 
that could be easily be identified, wave-
length (color) dependent distances for 
perceived brightness levels were obtained 
and compared to the Nominal Ocular 
Hazard Distance (NOHD). An algo-
rithm was created to indicate whether 
the experience had exceeded maximum 
permissible exposure and therefore 
warranted medical examination. A 
symptoms list and an Amsler grid were 
included to account for visual distur-
bances and general eye problems. Five 
experts in laser study and/or ophthal-
mology, in addition to a flight operations 
inspector, were consulted throughout 
the ALESA’s creation. 
A five point Likert-type scale was 
developed to gauge the attitudes of pilots 
and flight crew on the use of the ALESA. 
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the patient’s cardiac history, preexisting 
comorbidities and cardiac procedure data 
were collected. We hypothesized that 
widely used cardiac procedures, including 
percutaneous coronary intervention 
(PCI), coronary artery bypass graft 
(CABG) surgery, valve surgery, and 
cardiac catheterization would be 
accurately coded in administrative 
databases when compared with a clinical 
registry.
We  e x a m i n e d  t h e  C I H I 
administrative database for all PCIs, 
CABG surgeries, cardiac valve surgeries, 
and cardiac catheterization procedures 
performed at 18 cardiac care centers in 
Ontario, Canada between the 2005 and 
2006 fiscal years. Cardiac procedures 
were matched between the CIHI and the 
CCN databases whether they occurred 
on the same day in the same patient at 
the same hospital site. We determined 
the positive predictive value (PPV) of 
CIHI coded procedures as the numbers 
of matching procedures divided by 
total procedure counts in CCN. As the 
procedure dates can be a common source 
of mismatch, we repeated the analysis 
after expanding the allowable window 
for matching to ±1 day. To determine 
the extent of the time window’s impact, 
we expanded the window for matching 
to ±7 days in a sensitivity analysis.
The PPV of the administratively 
coded CABG surgery from the CIHI 
databases was 97 percent. For valve 
surgery procedures, the accuracy of 
administrative databases was 96 per-
cent. When compared against the CCN 
clinical registries, the coding accuracy 
of both PCI and cardiac catheterization 
were 94 percent. When the procedure 
date window was expanded from the 
same day to ±1 day, the PPV improved 
to 96 percent for PCI and exceeded 98 
percent for CABG surgery, 97 percent for 
valve surgery, and 95 percent for cardiac 
catheterization.
In sensitivity analyses, we expanded 
the matching date window to ±7 days 
(Figure). The highest increase in PPV 
occurred when the date window was 
widened by ± 1 day, and there were only 
minimal increments in predictive value 
thereafter (Figure).
In summary, our evaluation suggests 
that administrative coding of CABG 
surgery, valve surgery, PCI, and cardiac 
catheterization procedures is valid, and 
therefore is a better alternative for out-
comes research because they are readily 
available, cheaper to prepare and at least 
as accurate as a province-wide prospec-
tive registry.
REFERENCES:
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Burden of cardiovascular disease in Canada. 
Can J Cardiol.19:997–1004.
2. Schneeweiss S, Avorn J. (2005). A review of 
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Design and Validation of the Aviation Laser Exposure Self-Assessment
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The study population consisted of 25 
male and female pilots and flight crew 
members who have experienced aviation 
laser beam exposure. Because the par-
ticipants were considered hard-to-find 
types of individuals, network sampling 
was used. After completing the ALSEA 
based on their most recent exposure, 
they indicated their level of agreement 
on six dimensions: time saving potential, 
likelihood of use, ease of completion, 
need, accuracy, and decrease in anxiety. 
The proportion agreeing (responding 
favorably) was found to be significant 
in all aspects of the ALESA except for 
its ability to decrease anxiety. Content 
validity was established by the expert’s 
judgment of the appropriateness of the 
ALESA and face validity was found by 
the participant’s responses. The ALSEA 
was shown to be of use to the aviation 
community and the CAA is currently 
distributing the tool throughout the 
United Kingdom. None of the par-
ticipants experienced permanent damage 
from their exposure and the probability 
Hig h ly  a c t i ve 
antiretro-
v i r a l  t h e r a p y 




formed HIV into 
a chronic disease 
requir ing long 
term fol low-up 
of HIV-infected 
pat ients. India 
has approximately 
2.3 million HIV-infected persons 
and Antiretroviral Therapy (ART) is 
Losses to Follow-up Among Patients Registered  
for Care at a Tertiary HIV Referral Center in Chennai, India 
Erik J. Blutinger, MS II 
Advisor: Sunil Solomon, 
P h . D . ,  M . P. H . ,  Y R 
Gaitonde Centre for AIDS 
Research and Education, 
Chennai, India
of such damage at this time is extremely 
low. As the power of lasers purchased by 
the public increases in the future, it will 
be desirable to establish the sensitivity 
and specificity of the ALESA.
REFERENCES:
1.  International Civil Aviation Organization. 
(2003). Manual on laser emitters and flight 
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available in India via the public and 
private sectors. While services such as 
physician consultation and ART costs in 
the government sector are free, patients 
are generally required to pay for these 
and other services in the private sector. 
Unfortunately, it is difficult to ascertain 
the efficacy of ART treatment since 
there is limited data on loss-to-follow 
up (LTFU) rates and factors associated 
with LTFU in India.
Our case control analysis comprised 
a subset of patients registered for care 
at YRGCARE (a private non-govern-
mental organization providing HIV 
clinical services in Chennai since 1993) 
between Jan. 1, 2004 and Dec. 31, 2009. 
Cases (LTFU) were defined as patients 
who did not have at least one visit 
between Jan. 1, 2010 and Dec. 31, 2010. 
“Project” patients included the subset of 
patients who were enrolled in clinical 
trials or projects and received some 
compensation for clinical care (e.g., free 
ART, free consultation, compensation 
for travel, etc.) and who were assigned 
retention staff. Logistic regression was 
used to identify factors associated with 
LTFU. 
Of 7,995 patients included in the 
analysis, 68.2 percent were male with 
a median age of 34 years. The overall 
2.  Nakagawara VB. Montgomery RW. Wood KJ. 
(2010) The illumination of aircraft at altitude 
by laser beams: a five-year study. FAA Civil 
Aerospace Medical Institute. 
3. Civil Aviation Authority, Safety Regulatory 
Group. CAP 789. Requirements and guidance 
material for operators illumination of aircraft 
by bright lights or lasers. www.caa.co.uk/
application.aspx?catid=33&pagetype=65&appi
d=11&mode=detail&id=3978.
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Kaplan-Meier Survival Estimateloss to follow-up rate was 38.1 per 100 
person-years p-y. Among those who were 
LTFU, there were 304 (3.8 percent) doc-
umented deaths. In univariate analysis, 
LTFU was less common in those with 
higher baseline CD4 count, higher CD4 
count at last visit to the clinic, being 
enrolled in a project and having initiated 
ART. LTFU was more common among 
patients who were older and unmarried. 
In multivariate analyses, persons were 
significantly less likely to be LTFU if 
they were enrolled in a project (OR: 
0.66; 95 percent CI: 0.58, 0.77), being 
initiated on ART (OR: 0.32, 95 percent 
CI: 0.26. 0.38) or married (OR: 0.71, 95 
percent CI: 0.57, 0.88). 
This clinical cohort exhibited a 
high-rate of LTFU as the majority of 
the losses occurred within the f irst 
month. Given the negative association of 
LTFU with being enrolled in a project, 
innovative strategies using incentives 
(e.g., conditional cash transfer, travel 
incentives) and peer-health workers in 
improving retention among patients 
needs to be evaluated for efficacy and 
cost-effectiveness, considering that cash 
incentives can improve HIV-positive 
patient follow-up.1 Given the high rate 
of mortality among patients LTFU 
compared to documented deaths in 
the clinical cohort, the impact of these 
deaths on survival analyses need to be 
examined. 
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Treatment.” Center for Global Develop-
ment. www.cgdev.org/content/publications/
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Ur i n a r y  t r a c t 
infections (UTIs), 
including acute 
cyst it is (infec-
tion of the lower 
u r ina r y  t r ac t) 
a n d  p y e l o n e -
phr it i s  (in fec-
t ion involv ing 
the kidney), are 
among the most 
frequently occur-
ring infections in 
humans.1 Among 
non-institutionalized elderly individ-
uals, UTIs are the second most common 
type of infection, representing approxi-
mately 25 percent of all infections.1 
We used data from The Surveillance 
The Rise of Ciprofloxacin-Resistant Urinary E. coli  
Among Older U.S. Outpatients, from 2000 to 2010
Gui l l e rmo Sanchez , 
M.P.H./P.A. candidate 
Advisor: Jose Bordon, 
M.D., Ph.D., Section 
of Infectious Disease, 
Providence Hospital
Network (TSN) to describe in vitro E. 
coli antimicrobial resistance among 
isolates collected from older outpatients 
(ages 65 and older) in the United States 
from 2000 to 2010. Details of this sur-
veillance system have been described 
previously.3 Susceptibility testing is 
performed on site by each laboratory in 
accordance with FDA-approved testing 
methods and interpreted using Clinical 
and Laboratory Standards Institute 
(CLSI) recommended breakpoints. The 
objective of this study was to examine 
trends and prevalence of the antimicro-
bial resistance of urinary E. coli isolates 
to commonly prescribed antimicrobial 
agents among older outpatients (65+) 
in the United States from 2000 to 2010. 
Susceptibility testing results from 
urinary isolates of E. coli (n = 2,555,999) 
were examined from U.S. outpatients 
from 2000 to 2010 (see Figure). The 
greatest increases in antimicrobial resis-
tance from 2000 to 2010 were observed 
for ciprofloxacin 6.0 percent to 29.5 
percent and TMP/SMX 16.3 percent 
to 26.8 percent, whereas nitrofurantoin 
1.5 percent to 2.8 percent demonstrated 
a small increase (see Table). In 2010, 
ampicillin, amoxicillin-clavulanate, and 
tetracycline demonstrated resistance 
rates of 45.7 percent, 7.0 percent, and 
24.9 percent, respectively. 
E. coli antimicrobial resistance 
among older U.S. outpatients increased 
markedly for ciprofloxacin and TMP/
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FIGURE:  Cumulative change in antimicrobial resistance in urinary E. coli isolates, 2000–10.
SMX from 2000 to 2010. Though 
rises in resistance have been reported 
previously for TMP/SMX, such sub-
stantial increases in E. coli resistance 
to ciprofloxacin have yet to be reported 
among older U.S. outpatients. These 
results highlight a disturbing trend of 
soaring resistance that will have a pro-
found effect on how UTIs are treated 
in the outpatient setting. When resis-
tant uropathogens such as E. coli are 
encountered, the likelihood of a clinical 
cure decreases and risk of recurrence 
increases.3 Additionally, resistance sig-
nificantly increases patient morbidity, 
costs of treatment, rates of hospital-
ization, and use of broader spectrum 
agents.4 As the availability of efficacious 
antimicrobial therapies dwindles in the 
wake of rising antimicrobial resistance, 
the population that will be most severely 
affected will be older adults like the ones 
represented in this study.
The strengths of this investigation 
include the large number of isolates, 
the long time period for which data 
were collected, and the variety of agents 
examined. Although passive surveillance 
systems such as TSN are suitable for 
examining patterns in antimicrobial 
resistance , they are generally not used to 
guide therapeutic use of empiric agents. 
Local susceptibility data that are col-
lected prospectively through active local 




























determining proper empirical therapy 
for the treatment of uncomplicated 
UTIs among individual patients. 
In summary, our study shows that 
from 2000 to 2010 E. coli antimicrobial 
resistance to ciprofloxacin and TMP/
SMX increased substantially among 
older outpatients in the United States, 
whereas lower resistance to nitrofuran-
toin remained low. Given the frequency 
with which UTIs are treated empirically, 
compounded with the speed that E. coli 
acquires resistance, judicious selection 
of empirical agents in the outpatient 
setting remains crucial. 
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 Total Isolates Percent Resistance Total Change
 DRUG 2000–10 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2000–10 P-value*
 IMP/SMX 2,034,254 17.9 17.8 18.1 18.2 19.4 20.2 20.8 21.9 22.9 23 24.2 6.3 <0.0001
 Ciprofloxacin 1,836,598 3 3.7 5 6.2 7.5 9.7 12.2 14.1 16 16.3 17.1 14.1 <0.0001
 Ampicillin 2,002,221 38.2 38.1 38.2 38.2 38.2 39.4 40.5 41.5 42.4 42.4 43.4 5.2 <0.0001
 Amox/Clav 759,749 5 4.1 5.3 4.5 3.7 3.8 5.6 8.2 9.9 6.6 5.3 0.3 0.0054
 Nitrofurantoin 1,972,633 0.8 1 1.1 1.1 1 1.1 1.4 1.5 1.5 1.6 1.6 0.8 <0.0001
 Tetracycline 580,328 22.6 22.1 22.1 21.1 21.9 22 23.5 23.7 24.4 24.5 24.9 2.3 <0.0001
NOTE: Isolates demonstrating intermediate susceptibility were not counted as resistant. Amox/Clav, Amoxicillin/Clavulanate; TMP-SMX, Trimethoprim/Sulfamethoxazole.
Comparison of 2010 vs. 200 antimicrobial resistance rates
TABLE: Annual Rates of Antimocrobial Resistance in Urinary Eschericha coli Isolates to Select Antimibrobials in United States Outpatients, 2000–10.
The serendipity of collaboration, ingenuity, and innovation 
have often stemmed from the desire to create something new 
from a variety of perspectives and sources of knowledge. 
This is exemplified in the medical field and incorporated 
in the theme of this year’s edition of Fusion. Inspired by 
this integration of research and clinical care, the cover is a 
fusion of two different mediums by two second-year medical 
students; an anatomical sketch of a heart (Aaron P. Wessell) 
and a photograph of a statue from the National Museum of 
the American Indian (Benjamin J. Trevias). 
The two mediums were chosen deliberately to showcase 
both contemporary and ancient elements to provide a dynamic 
composite cover.
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Fusion is the annual student-run scientific journal of The 
George Washington University’s William H. Beaumont 
Medical Research Honor Society. It was created to 
showcase student achievements in basic science and 
clinical research, public health, medical education, and 
international health-related travel experiences.
Submissions from the classes of 2013, 2014, 
and 2015, as well as the incoming class of 2016 
for next year’s edition of the journal will be 
accepted beginning in September 2012. For more 
information, please contact the Beaumont Society at 
gwbeaumont@gmail.com. 
Contributions to the publishing costs of this journal 
are appreciated. If you would like to make a 
donation, please contact us at 
gwbeaumont@gmail.com. 
All proceeds will go toward 
the publishing costs for next year’s journal.
